Episode 442: The 2026 ACTRIMS Forum (Part 2) with Dr. Jeffrey Cohen, Dr. Daniel Ontaneda, and Kristine Werner Ozug

Episode 442: The 2026 ACTRIMS Forum (Part 2) with Dr. Jeffrey Cohen, Dr. Daniel Ontaneda, and Kristine Werner Ozug

Welcome back to Part Two of our coverage of the 2026 ACTRIMS Forum. This week, we shift our focus to emerging therapies and clinical insights that are re-shaping the future of MS care. From the latest information on stem cell transplantation to evolving treatment strategies to the labels used to describe MS, we're breaking down the complex science into the conversations that matter most to the MS community.

Joining me to discuss one of the most significant presentations from the 2026 ACTRIMS Forum is Dr. Jeffrey Cohen, who opened the event with the Kenneth P. Johnson Memorial Lecture.

Dr. Cohen's lecture, "AHSCT: Current Status and Remaining Questions," tackled a topic of massive interest to both clinicians and the MS community: Autologous Hematopoietic Stem Cell Transplantation (AHSCT). Often described as "resetting" the immune system, AHSCT is a complex and life-changing procedure that continues to evolve.

In our conversation, Dr. Cohen delves deeper into his lecture, discussing transplant efficacy, the best candidates for AHSCT, the optimal time to consider AHSCT, and how people living with MS may qualify to participate in a clinical trial comparing the benefits of AHSCT with those of high-efficacy disease-modifying therapies.

Joining me for a deep dive into the future of MS care is Dr. Daniel Ontaneda. Our wide-ranging conversation explores the cutting edge of clinical practice and research, including the "early vs aggressive" treatment debate, how incorporating new imaging biomarkers will lead to faster, more reliable, and more accurate MS diagnoses, and whether the current disease classifications still serve the best interests of patient care.

While MS research conferences like the ACTRIMS Forum are never short on world-class expert opinions and groundbreaking data, one perspective is often missing from the room: the voice of someone living with the disease.

That's why I was so glad to have Kristine Werner Ozug, a valued member of the RealTalk MS team, on the ground with me. As someone living with MS, Kristine brings a vital lens to these scientific sessions. After the final gavel fell, I sat down with her to get her "patient-first" perspective on the research that mattered most to her and what she's taking away from this year's Forum.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: The 2026 ACTRIMS Forum (Part 2) :22

Dr. Jeffrey Cohen takes us on a deep-dive into Autologous Hematopoietic Stem Cell Transplantation (AHSCT) 1:23

Dr. Daniel Ontaneda discusses the ways that today's MS research will impact tomorrow's MS care 10:44

Kristine Werner Ozug shares her "patient-first" perspective on the research that mattered most to her and what she's taking away from the 2026 ACTRIMS Forum 28:17

Share this episode 43:31

Next week's episode 43:54

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/442

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: jon@realtalkms.com
Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Support Jon at WALK MS
https://realtalkms.com/walkms

Find out about ABLEnow Accounts
https://ablenow.com

JOIN: The RealTalk MS Facebook Group
https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review
http://www.realtalkms.com/review

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 442
Guests: Dr. Jeffrey Cohen, Dr. Daniel Ontaneda, and Kristine Werner Ozug

Privacy Policy

Avsnitt(502)

Episode 448: At the National MS Society's Public Policy Conference with David, Cliff, and Michelle

Episode 448: At the National MS Society's Public Policy Conference with David, Cliff, and Michelle

Last week, about 170 MS activists from across the country gathered in Washington, D.C. to participate in the National MS Society's Public Policy Conference. It's hard to come away from this event and ...

30 Mars 31min

Episode 447: Walking with Many Sisters Toward a Cure with Brigitte Delaney

Episode 447: Walking with Many Sisters Toward a Cure with Brigitte Delaney

In 1988, there were just 42 Walk MS events, raising approximately $4 million. In 2025, there were 170 events across the country that raised over $30 million. As the largest private funder of MS resear...

23 Mars 23min

Episode 446: MS Advocacy and the National MS Society's Public Policy Conference with Steffany Stern

Episode 446: MS Advocacy and the National MS Society's Public Policy Conference with Steffany Stern

175 MS activists are heading to Washington, D.C. next week for the National MS Society's Public Policy Conference. Their mission: to bring the concerns of the MS community directly to lawmakers on Cap...

16 Mars 34min

Episode 445: It's MS Awareness Week with Kristine Werner Ozug and Kim, Kim, and Kim

Episode 445: It's MS Awareness Week with Kristine Werner Ozug and Kim, Kim, and Kim

It's MS Awareness Week, and this year we're diving into a theme that hits home for millions: Unseen MS. Multiple sclerosis is a master of disguise; it can be entirely invisible to the naked eye while ...

9 Mars 40min

Episode 444: Treating MS with a GLP-1 with Dr. Ellen Mowry

Episode 444: Treating MS with a GLP-1 with Dr. Ellen Mowry

You know them by their trade names such as Ozempic, Wegovy, Mounjaro, and Zepbound. This class of medications is known as GLP-1 receptor agonists. And while they are best known for managing diabetes a...

2 Mars 31min

Episode 443: The 2026 ACTRIMS Forum (Part 3) with Dr. Helen Tremlett, Dr. Ilana Katz Sand, and Kathy Smith

Episode 443: The 2026 ACTRIMS Forum (Part 3) with Dr. Helen Tremlett, Dr. Ilana Katz Sand, and Kathy Smith

Welcome back to the third and final part of our coverage of the 2026 ACTRIMS Forum. This week's episode bridges the gap between groundbreaking clinical research and the nuanced reality of living with ...

23 Feb 35min

Episode 441: The 2026 ACTRIMS Forum with Dr. Manuel Friese, Dr. Amit Bar-Or, and Dr. Haritha Desu

Episode 441: The 2026 ACTRIMS Forum with Dr. Manuel Friese, Dr. Amit Bar-Or, and Dr. Haritha Desu

Last week, over 1,400 scientists and clinicians gathered in San Diego, California, at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis annual meeting, better known as the A...

9 Feb 33min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-missbruk-medberoende-2
inga-beiga-morsor
rss-jossan-nina
alska-oss
rss-vuxna-pa-latsas
sexnoveller-deluxe
angestpodden
not-fanny-anymore
sova-med-dan-horning
johannes-hansen-podcast
rss-viktmedicinpodden
brottarbroder
vinterpasset
sa-in-i-sjalen
sag-det-bara
rss-sjalsligt-avkladd
rss-the-house-podcast-3
giggles-med-wiggles
till-sangs